Cyclophosphamide metabolism in children with Fanconi's anaemia

Bone Marrow Transplantation

Volumn 24, Issue 2, 1999, Pages 123-128

  Yule, S M ^a   Price, L ^b   Cole, M ^b   Pearson, A D J ^b   Boddy, A V ^b  

^a NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

^b NONE

Author keywords

Cyclophosphamide; Drug metabolism; Fanconi's anaemia

Indexed keywords

CYCLOPHOSPHAMIDE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; FANCONI ANEMIA; FEMALE; HIGH PERFORMANCE THIN LAYER CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; SCHOOL CHILD;

EID: 0032773194     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701868     Document Type: Article

References (39)

1. Auerbach AD, Woman SR. Susceptibility of Fanconi anaemia fibroblasts to chromosome damage by carcinogens. Nature 1976; 261: 494-496.
2. Berger R, Bernheim A, Gluckman E. In vitro effect of cyclophosphamide metabolites on chromosomes of Fanconi's anaemia patients. Br J Haematol 1980; 45: 565-568.
3. Alter BP. Fanconi's anaemia and its variability. Br J Haematol 1993; 85: 9-14.
4. Gluckman E, Auerbach AD, Horowitz MM et al. Bone marrow transplantation for Fanconi anaemia. Blood 1995; 86: 2856-2862.
5. Gluckman E, Devergie A, Schaison G et al. Bone marrow transplantation in Fanconi anaemia. Br J Haematol 1980; 45: 557-564.
6. Deeg HJ, Storb R, Thomas ED et al. Fanconi's anaemia treated by allogeneic marrow transplantation. Blood 1983; 61: 954-959.
7. Kohli-Kumar M, Morris C, DeLaat C et al. Bone marrow transplantation in Fanconi anaemia using matched sibling donors. Blood 1994; 84: 2050-2054.
8. Flowers MED, Zanis J, Pasquini R et al. Marrow transplantation for Fanconi anaemia: conditioning with reduced doses of cyclophosphamide without radiation. Br J Haematol 1996; 92: 699-706.
9. Gluckman E. Allogeneic bone marrow transplantation in Fanconi anaemia. Bone Marrow Transplant 1996; 18 (Suppl. 3): S33-S35.
10. Matsumoto A, Vos J-MH, Hanawalt PC. Repair analysis of mitomycin C-induced DNA crosslinking in ribosomal RNA genes in lymphoblastoid cells from Fanconi's anaemia patients. Mutat Res 1989; 217: 185-192.
11. Marathi UK, Howell SR, Ashmun RA et al. The Fanconi anaemia complementation group C protein corrects DNA interstrand cross-link-specific apoptosis in HSC536N cells. Blood 1996; 88: 2298-2305.
12. Poot M, Gross O, Epe B et al. Cell cycle defect in connection with oxygen and iron sensitivity in Fanconi anaemia lymphoblastoid cells. Exp Cell Res 1996; 222: 262-268.
13. Clarke AA, Philpott NJ, Gordon-Smith EC et al. The sensitivity of Fanconi anaemia group C cells to apoptosis induced by mitomycin C is due to oxygen radical generation, not DNA crosslinking. Br J Haematol 1997; 96: 240-247.
14. Ruppitsch W, Meisslitzer C, Weirich-Schwaiger H et al. The role of oxygen metabolism for the pathological phenotype of Fanconi anaemia. Hum Genet 1997; 99: 710-719.
15. Sladek NE. Metabolism of oxazaphosphorines. Pharmacol Ther 1988; 37: 301-355.
16. Dockham PA, Lee M-O, Sladek NE. Identification of human liver aldehyde dehydrogenases that catalyse the oxidation of aldophosphamide and retinaldehyde. Biochem Pharmacol 1992; 43: 2453-2469.
17. Yule SM, Boddy AV, Cole M et al. Cyclophosphamide metabolism in children. Cancer Res 1995; 55: 803-809.
18. Yule SM, Boddy AV, Pearson ADJ, Idle JR. Reproducibility of methods relating to cyclophosphamide metabolic studies - commentary. J Natl Cancer Inst 1993; 85: 1249-1250.
19. D'Argenio DZ, Schumitzy A. Adapt II Users Guide. Biomedical Simulations Resource: University of Southern California, Los Angeles, 1992.
20. Juma FD, Ogada T. Pharmacokinetics of cyclophosphamide in Kenyan African Children with lymphoma. Br J Clin Pharmacol 1984; 18: 106-107.
21. Tasso M, Boddy AV, Price L et al. Pharmacokinetics and metabolism of cyclophosphamide in paediatric patients. Cancer Chemother Pharmacol 1992; 30: 207-211.
22. Gardner M, Jusko W. The effect of age and sex on theophylline clearance. Pediatr Pharmacol 1982; 2: 157-169.
23. Crom WR, Relling MV, Christensen ML et al. Age related differences in hepatic drug clearance in children: studies with lorazepam and antipyrine. Clin Pharmacol Ther 1991; 50: 132-140.
24. Bramwell V, Calvert RT, Edwards G et al. The disposition of cyclophosphamide in a group of myeloma patients. Cancer Chemother Pharmacol 1979; 3: 253-259.
25. Alberts DS, Mason-Liddil N, Plezia PM et al. Lack of ranitidine effects on cyclophosphamide bone marrow toxicity or metabolism. A placebo controlled clinical trial. J Natl Cancer Inst 1991; 83: 1739-1743.
26. Chang TKH, Yu L, Maurel P, Waxman DJ. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res 1997; 57: 1946-1954.
27. Wing LM, Miners JO. Cotrimoxazole as an inhibitor of oxidative drug metabolism: effects of trimethoprim and sulphamethoxazole separately and combined on tolbutamide disposition. Br J Clin Pharmacol 1985; 20: 482-485.
28. O'Reilly RA. Stereoselective interaction of trimethoprim-sulfamethoxazole with the separated enantiomorphs of racemic warfarin in man. New Engl J Med 1980; 302: 33-35.
29. Yule SM, Boddy AV, Cole M et al. Cyclophosphamide pharmacokinetics in children. Br J Clin Pharmacol 1996; 41: 13-19.
30. Blum RA, Wilton JH, Hilligoss DM et al. Effect of fluconazole on the disposition of phenytoin. Clin Pharmacol Ther 1991; 49: 420-425.
31. Jurima-Romet M, Crawford K, Cyr T, Inaba T. Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals. Drug Metab Dispos 1994; 22: 849-857.
32. Ervine CM, Matthew DE, Brennan B, Houston JB. Comparison of ketoconazole and fluconazole as cytochrome P450 inhibitors. Use of steady-state infusion approach to achieve plasma concentration-response relationships. Drug Met Dispos 1996; 24: 211-215.
33. Busse D, Busch FW, Bohnenstengel F et al. Dose escalation of cyclophosphamide in patients with breast cancer: consequences for pharmacokinetics and metabolism. J Clin Oncol 1997; 15: 1885-1896.
34. Shaw IC, Graham MI. Mesna-A short review. Cancer Treat Rev 1987; 14: 67-86.
35. Yabe M, Yabe H, Matsuda M et al. Bone marrow transplantation for Fanconi anaemia. Adjustment of the dose of cyclophosphamide for preconditioning. Am J Pediatr Hematol/Oncol 1993; 15: 377-382.
36. White RE, Coon MJ. Oxygen activation by cytochrome P-450. Annu Rev Biochem 1980; 49: 315-356.
37. Paller MS, Jacob HS. Cytochrome P-450 mediates tissue-damaging hydroxyl radical formation during reoxygenation of the kidney. Proc Natl Acad Sci USA 1994; 91: 7002-7006.
38. Youssoufian H, Hoshino T, Lui JM et al. Binding of the Fanconi anaemia group C protein to NADPH cytochrome P-450 reductase: implications for mitomycin C activation. Blood 1997; 90: 438a.
39. Moore MJ. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokin 1991; 20: 194-208.